For one of these FGFRs, FGFR3, these alterations can take the form of small changes, called mutations, or larger changes where FGFR3 is fused to another gene, called fusions, both of which can ...

These 3D renderings of mouse skulls clearly show the effects of RUNX2 deficiency. Fgfr3-creER mice, which were the control group, and Fgfr3-Runx2c ...

The recent approval of Balversa (erdafitinib) is crucial for patients with metastatic bladder cancer who also have FGFR3 gene mutations, an expert told CURE®. In January, the Food and Drug ...

Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300 First results from SURF301 phase I clinical trial ...

The same gene can play "good cop, bad cop" – While FGFR3 gain-of-function variants cause achondroplasia, reduced FGFR3 activity has been linked to CATSHL syndrome, marked by unusually long limbs ...

For one of these FGFRs, FGFR3, these alterations can take the form of small changes, called mutations, or larger changes where FGFR3 is fused to another gene, called fusions, both of which can ...

Over 97% of cases of achondroplasia are due to a mutation in the fibroblast growth factor receptor (FGFR) 3 gene. ... TYRA-300 is an investigational, oral, FGFR3-selective inhibitor.

First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors ...

Achondroplasia is caused by a spontaneous mutation in a specific gene called FGFR3. About 98% of cases result from the exact same change in the DNA in this gene.

Alterations in the FGFR3 gene are found in 15%-20% of advanced urothelial cancer cases. These mutations are particularly common in the luminal subtype of the disease.

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4.

Citation: Advanced bladder cancer patients with alterations in FGFR3 gene respond well to investigational drug: Clinical trial (2024, October 24) retrieved 13 May 2025 from https://medicalxpress ...